PwC's Glenn Hunzinger stops by to discuss the Pharmaceutical and life sciences deals insights: 2021 midyear outlook report, showcasing the PLS sector returned to normal deal activity with strong deal volume. Plus, Omar Ford, MD+DI's Managing Editor gives his take on the controversial Illumina/Grail merger.